GlassScriptPhysician profile
Zaheer Ahmed
NPI 1205178456
$3,382.97
in general payments reported to CMS, 2019-2025
45 companies · $1,142 in 2025
The $1,142 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $121 · 2021: $182 · 2022: $254 · 2023: $584 · 2024: $936 · 2025: $1,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,265 · Education: $397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,265.17 |
| Education | $396.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $275.15 | 2023-2025 | Jakafi, Monjuvi |
| Pfizer INC. | $269.01 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $206.92 | 2023-2025 | Tagrisso, Imfinzi, Calquence |
| Biogen, INC. | $190.20 | 2019-2025 | Vumerity, Tysabri |
| Seagen INC. | $185.83 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $176.65 | 2023-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Genzyme Corporation | $149.93 | 2021-2025 | |
| Janssen Biotech, INC. | $146.35 | 2023-2025 | Imbruvica, Darzalex, Tecvayli |
| Sobi, INC | $124.75 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $115.01 | 2023 | Imbruvica |
| Bayer Healthcare Pharmaceuticals INC. | $114.26 | 2023-2025 | |
| Adc Therapeutics America, INC. | $111.41 | 2024 | |
| Emd Serono, INC. | $110.61 | 2022-2024 | Mavenclad |
| Abbvie INC. | $99.31 | 2024 | |
| Novartis Pharmaceuticals Corporation | $82.82 | 2020-2025 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $73.45 | 2022-2024 | Rybrevant, Xarelto |
| E.R. Squibb & Sons, L.L.C. | $64.40 | 2023-2025 | Opdivo, Opdualag |
| Glaxosmithkline, LLC. | $62.69 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Lilly USA, LLC | $61.39 | 2019-2024 | Retevmo, Jaypirca, Verzenio |
| Celgene Corporation | $58.82 | 2023-2024 | Reblozyl |
| Pharmaessentia USA Corporation | $57.77 | 2023-2025 | Besremi |
| Acorda Therapeutics, INC | $56.81 | 2022-2023 | Inbrija |
| Astellas Pharma US INC | $47.49 | 2025 | Vyloy, Xtandi |
| Eisai INC. | $47.07 | 2020-2025 | |
| Array Biopharma INC | $45.67 | 2024-2025 | Mektovi, Xalkori, Lorbrena |
| Daiichi Sankyo INC. | $44.42 | 2024-2025 | Datroway, Enhertu |
| Beigene USA, INC. | $31.26 | 2024 | Brukinsa |
| Gilead Sciences, INC. | $30.00 | 2025 | Trodelvy |
| Pharmacosmos Therapeutics INC. | $25.83 | 2025 | Monoferric |
| Arbor Pharmaceuticals, INC. | $25.30 | 2019-2020 | |
| Servier Pharmaceuticals LLC | $25.05 | 2024 | |
| Geron Corporation | $24.90 | 2025 | Rytelo |
| Verity Pharmaceuticals INC. | $24.69 | 2025 | Tlando |
| Regeneron Healthcare Solutions, INC. | $23.10 | 2025 | Lynozyfic |
| Genentech USA, INC. | $21.74 | 2024 | Lunsumio, Polivy, Columvi |
| Dendreon Pharmaceuticals LLC | $21.64 | 2025 | Provenge |
| Amgen INC. | $20.69 | 2023 | Lumakras |
| Allergan, INC. | $20.45 | 2020 | |
| Blueprint Medicines Corporation | $18.46 | 2023 | Ayvakit |
| Rigel Pharmaceuticals, INC. | $17.42 | 2025 | Gavreto, Rezlidhia, Tavalisse |
| Tolmar, INC. | $15.62 | 2025 | Eligard, Rubraca |
| Pharmaand Gmbh | $15.62 | 2025 | Rubraca |
| Caris Mpi, INC. | $14.76 | 2025 | Mi Cancer Seek |
| Portola Pharmaceuticals, LLC | $14.31 | 2019 | |
| Iovance Biotherapeutics, INC. | $13.94 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zaheer Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.